Santen facts and figures
€1.87 billion revenue
(approx. 266.3 billion yen)
94% of revenue from prescription ophthalmic pharmaceuticals
Sales outside Japan account for 35% of corporate revenue
4,300 employees globally
Products supplied in over 60 countries and regions
Dedicated facilities for ongoing research and development: Nara (Japan), Evry (France), Emeryville (US), etc.
Three manufacturing sites: Noto and Shiga (Japan), Suzhou (China)
Source: Santen Pharmaceutical Co., Ltd. Fiscal year (FY2021) ended 31 March 2022.